دورية أكاديمية
CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation.
| العنوان: | CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation. |
|---|---|
| المؤلفون: | Lin Z; Department of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Tang X; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Cao Y; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Yang L; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Jiang M; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Li X; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Min J; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Chen B; Department of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China., Yang Y; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Gu C; Department of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China. |
| المصدر: | Aging [Aging (Albany NY)] 2022 Nov 28; Vol. 14 (22), pp. 9264-9279. Date of Electronic Publication: 2022 Nov 28. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals, LLC Country of Publication: United States NLM ID: 101508617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-4589 (Electronic) Linking ISSN: 19454589 NLM ISO Abbreviation: Aging (Albany NY) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, NY : Impact Journals, LLC |
| مواضيع طبية MeSH: | Multiple Myeloma* , Receptors, Chimeric Antigen*, Animals ; Humans ; Mice ; Cell Proliferation ; MAP Kinase Signaling System ; ras GTPase-Activating Proteins ; Receptors, Cell Surface ; Signaling Lymphocytic Activation Molecule Family |
| مستخلص: | Multiple myeloma (MM) is an incurable plasma cell malignancy, while CAR-T therapy offers a new direction for the treatment of MM. Recently, signaling lymphocytic activation molecule family 3 (CD229), a cell surface immune receptor belonging to the signaling lymphocyte activating molecule family (SLAMF), is emerging as a CAR-T therapeutic target in MM. However, a clear role of CD229 in MM remains elusive. In this study, MM patients with elevated CD229 expression achieved poor prognosis by analyzing MM clinical databases. In addition, CD229 promoted MM cell proliferation in vitro as well as in xenograft mouse model in vivo . Mechanism study revealed that CD229 promoted MM cell proliferation by regulating the RAS/ERK signaling pathway. Further exploration employed co-immunoprecipitation coupled with mass spectrometry to identify RASAL3 as an important downstream protein of CD229. Additionally, we developed a co-culture method combined with the immunofluorescence assay to confirm that intercellular tyrosine phosphorylation mediated self-activation of CD229 to activate RAS/ERK signaling pathway via interacting with RASAL3. Taken together, these findings not only demonstrate the oncogenic role of CD229 in MM cell proliferation, but also illustrate the potential of CD229 as a promising therapeutic target for MM treatment. |
| التعليقات: | Erratum in: Aging (Albany NY). 2023 Aug 28;15(16):8528-8529. (PMID: 37635436) |
| References: | Front Immunol. 2021 Apr 16;12:654839. (PMID: 33936082) Front Cell Dev Biol. 2019 Apr 16;7:50. (PMID: 31041312) J Immunol. 2001 Oct 1;167(7):3668-76. (PMID: 11564780) Leukemia. 2015 Mar;29(3):689-95. (PMID: 25027515) Lancet. 2021 Jan 30;397(10272):410-427. (PMID: 33516340) J Immunol. 2005 Jun 1;174(11):7033-42. (PMID: 15905546) Cell. 2017 Jun 29;170(1):17-33. (PMID: 28666118) Clin Pharmacokinet. 2020 Jul;59(7):849-856. (PMID: 32112275) Clin Transl Med. 2022 Feb;12(2):e684. (PMID: 35184390) Leuk Lymphoma. 2009 Jan;50(1):137-40. (PMID: 19152174) Nat Rev Cancer. 2011 Oct 13;11(11):761-74. (PMID: 21993244) Curr Drug Targets. 2011 Apr;12(4):563-78. (PMID: 21226671) Med Oncol. 2015 Mar;32(3):81. (PMID: 25698537) Cancers (Basel). 2021 May 27;13(11):. (PMID: 34072068) J Immunol. 2013 Sep 15;191(6):2989-98. (PMID: 23956418) Drugs. 2017 Jan;77(1):85-96. (PMID: 28032244) Trends Immunol. 2010 Aug;31(8):295-302. (PMID: 20650688) J Immunol. 2006 Jan 1;176(1):291-300. (PMID: 16365421) Nat Commun. 2020 Feb 7;11(1):798. (PMID: 32034142) Cytometry B Clin Cytom. 2018 May;94(3):509-519. (PMID: 29316178) Cytometry B Clin Cytom. 2016 Jan;90(1):91-100. (PMID: 26130131) Blood Cancer J. 2021 Apr 29;11(4):84. (PMID: 33927192) Trends Biotechnol. 2022 Jul;40(7):875-890. (PMID: 35078657) Mol Cancer. 2021 Jun 5;20(1):84. (PMID: 34090465) Ann N Y Acad Sci. 2011 Jan;1217:32-44. (PMID: 21091715) Leuk Res. 2014 Jan;38(1):121-30. (PMID: 24239173) Mol Med Rep. 2020 Jan;21(1):420-428. (PMID: 31746389) Cancers (Basel). 2021 Jan 13;13(2):. (PMID: 33451089) Blood. 2010 Oct 7;116(14):2543-53. (PMID: 20574050) Eur J Immunol. 2015 May;45(5):1512-23. (PMID: 25652366) J Hematol Oncol. 2021 Jun 9;14(1):90. (PMID: 34108020) Hum Vaccin Immunother. 2015;11(7):1606-11. (PMID: 26001047) Clin Exp Med. 2019 Feb;19(1):133-141. (PMID: 30291461) Nat Rev Immunol. 2009 Jan;9(1):39-46. (PMID: 19079134) Blood. 2008 Nov 15;112(10):4017-23. (PMID: 18669875) J Immunol. 2005 May 15;174(10):5977-86. (PMID: 15879090) Blood. 2006 Sep 15;108(6):2020-8. (PMID: 16728703) Oncogene. 2022 Mar;41(10):1482-1491. (PMID: 35075244) J Leukoc Biol. 2019 May;105(5):947-954. (PMID: 30791129) PLoS One. 2016 Apr 07;11(4):e0153236. (PMID: 27054584) Immunol Lett. 2011 Jan 30;134(2):122-8. (PMID: 20923684) Cytometry B Clin Cytom. 2016 Jan;90(1):81-90. (PMID: 26287276) J Clin Invest. 2020 Apr 1;130(4):1565-1575. (PMID: 32149732) Mol Cancer Res. 2020 Apr;18(4):632-643. (PMID: 31974290) Blood. 2013 Jan 10;121(2):318-28. (PMID: 23169779) Signal Transduct Target Ther. 2021 Oct 7;6(1):361. (PMID: 34620840) Med Oncol. 2010 Jun;27 Suppl 1:S14-24. (PMID: 20035387) JCO Oncol Pract. 2021 Jul;17(7):405-413. (PMID: 34003675) Front Cell Dev Biol. 2021 Apr 21;9:675939. (PMID: 33968945) Biomed Rep. 2018 Sep;9(3):241-246. (PMID: 30271600) PLoS One. 2013 Dec 20;8(12):e82918. (PMID: 24376606) |
| فهرسة مساهمة: | Keywords: CD229; RAS; RASAL3; multiple myeloma |
| المشرفين على المادة: | 0 (LY9 protein, human) 0 (ras GTPase-Activating Proteins) 0 (RASAL3 protein, human) 0 (Receptors, Cell Surface) 0 (Receptors, Chimeric Antigen) 0 (Signaling Lymphocytic Activation Molecule Family) |
| تواريخ الأحداث: | Date Created: 20221129 Date Completed: 20221212 Latest Revision: 20231207 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9740379 |
| DOI: | 10.18632/aging.204405 |
| PMID: | 36445333 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1945-4589 |
|---|---|
| DOI: | 10.18632/aging.204405 |